These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 446904)

  • 1. Long-term continuous intravenous insulin therapy with a portable insulin dosage-regulating apparatus.
    Irsigler K; Kritz H
    Diabetes; 1979 Mar; 28(3):196-203. PubMed ID: 446904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brittle diabetes: long-term control with a portable, continuous, intravenous insulin infusion system.
    Bayliss J
    Br Med J (Clin Res Ed); 1981 Nov; 283(6301):1207-9. PubMed ID: 6797511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia.
    Pickup JC; Keen H; Parsons JA; Alberti KG
    Br Med J; 1978 Jan; 1(6107):204-7. PubMed ID: 340000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preprogrammed insulin infusion with a portable pump system.
    Irsigler K; Kritz H; Kaspar L; Brändle J; Koller W; Franetzki M
    Horm Metab Res Suppl; 1979; (8):193-7. PubMed ID: 119699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between multi-injection and continuous subcutaneous insulin therapy in insulin-dependent diabetic inpatients.
    Saibene V; Melandri M; Brembilla L; Spotti D; Pozza G
    Acta Diabetol Lat; 1981; 18(1):45-50. PubMed ID: 7010856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term, ambulatory, subcutaneous insulin infusion versus multiple daily injections in brittle diabetic patients.
    Barbosa J; Menth L; Eaton J; Sutherland D; Freier EF; Najarian J
    Diabetes Care; 1981; 4(2):269-74. PubMed ID: 7011745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in glucagon levels after four to five weeks of glucoregulation by portable insulin infusion pumps.
    Raskin P; Pietri A; Unger R
    Diabetes; 1979 Nov; 28(11):1033-5. PubMed ID: 488544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting insulin requirements for a portable insulin pump using the Biostator. Evidence for reversible insulin resistance in poorly controlled type I diabetics.
    Mayfield RK; Sullivan FM; Colwell JA; Wohltmann HJ
    Diabetes; 1983 Oct; 32(10):908-14. PubMed ID: 6352376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A portable system for continuous intravenous insulin delivery: characteristics and results in diabetic patients.
    Hanna AK; Minuk HL; Albisser AM; Marliss EB; Leibel BS; Zinman B
    Diabetes Care; 1980; 3(1):1-8. PubMed ID: 6996955
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of a portable insulin infusion pump for outpatient management of brittle diabetes.
    Kitabchi AE; Fisher JN; Burghen GA; Gaylord MS; Blank NM
    Diabetes Care; 1979; 2(5):421-4. PubMed ID: 510142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diabetes therapy with continuous insulin infusion by a portable pump: metabolic effects of short-term treatment and long-term results in problem patients].
    Schernthaner G; Graninger W; Kwasny W; Prager R; Otto C
    Acta Med Austriaca; 1982; 9(5-6):205-13. PubMed ID: 6762034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term ambulatory peritoneal insulin infusion of brittle diabetes with portable pumps: comparison with intravenous and subcutaneous routes.
    Selam JL; Slingeneyer A; Hedon B; Mares P; Beraud JJ; Mirouze J
    Diabetes Care; 1983; 6(2):105-11. PubMed ID: 6406198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diabetic control with a portable insulin infusion pump for 7 weeks (author's transl)].
    Irsigler K; Kritz H; Koller W; Kaspar L; Mader R; Franetzki M
    Med Klin; 1978 Dec; 73(49):1738-43. PubMed ID: 723761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of severely brittle diabetes by continuous subcutaneous and intramuscular insulin infusions: evidence for a defect in subcutaneous insulin absorption.
    Pickup JC; Home PD; Bilous RW; Keen H; Alberti KG
    Br Med J (Clin Res Ed); 1981 Jan; 282(6261):347-50. PubMed ID: 6780019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Considerations for the programming of an open-loop insulin infusion device from the biostator glucose controller.
    Service FJ; Rizza RA; Westland RE; Hall LD; Nelson RL; Haymond MW; Clemens AH; Gerich JE
    Diabetes Care; 1980; 3(2):278-84. PubMed ID: 6993141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoglycemic coma associated with subcutaneous insulin infusion by portable pump.
    Lock DR; Rigg LA
    Diabetes Care; 1981; 4(3):389-91. PubMed ID: 7047116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basal-rate intravenous insulin infusion compared to conventional insulin treatment in patients with type II diabetes. A prospective crossover trial.
    Blackshear PJ; Roussell AM; Cohen AM; Nathan DM
    Diabetes Care; 1989; 12(7):455-63. PubMed ID: 2667926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical application of pre-programmed insulin infusion: continuous subcutaneous insulin therapy with a portable infusion system.
    Pickup JC; Viberti GC; Keen H; Parsons JA; Alberti KG
    Horm Metab Res Suppl; 1979; (8):202-4. PubMed ID: 395081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormonal and metabolic profiles in insulin-dependent diabetics under subcutaneous conventional and artificial endocrine pancreas (glucose continuous insulin infusion system Biostator) treatment.
    Calabrese G; Bueti A; Santeusanio F; Giombolini A; Zega G; Bellomo G; Antonella MA; Angeletti G; Massi-Benedetti M; Brunetti P
    J Endocrinol Invest; 1983 Feb; 6(1):1-8. PubMed ID: 6341441
    [No Abstract]   [Full Text] [Related]  

  • 20. Control of insulin-dependent diabetes with portable miniaturized infusion systems.
    Hepp KD; Renner R; Piwernetz K; Mehnert H
    Diabetes Care; 1980; 3(2):309-13. PubMed ID: 6993145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.